Page last updated: 2024-10-30

leflunomide and Dyslipidemias

leflunomide has been researched along with Dyslipidemias in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

ExcerptRelevanceReference
"Leflunomide is an antirheumatic drug whose administration to HIV-1-infected persons effectively decreases T-cell turnover and activation."1.38Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. ( Baldelli, F; Basile, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mencarelli, A1
Francisci, D1
Renga, B1
D'Amore, C1
Cipriani, S1
Basile, F1
Schiaroli, E1
Baldelli, F1
Fiorucci, S1

Other Studies

1 other study available for leflunomide and Dyslipidemias

ArticleYear
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner.
    Antiviral therapy, 2012, Volume: 17, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyslipidemias; Epididymis; Fatty Liver; HIV Protea

2012